Experience

Empress Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• • Oct 2021 - Present

• • Oct 2020 - Oct 2021

  Leading Drug Discovery in a Flagship NewCo with responsibility for Med Chem, Chemical Biology, and Synthetic Biology



Nimbus Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Director, Chemistry

  • Apr 2018 - Oct 2020

  • Chemistry Lead in a virtual Drug Discovery model • Partnering with Schrodinger and with Biology/Molecular Sciences/DMPK • Drove two programs from Hit Gen to LO-like profile (potency, selectivity, PK) in 12 months each • New Target proposal chosen for possible portfolio entry • Chemistry Lead in a virtual Drug Discovery model • Partnering with Schrodinger and with Biology/Molecular Sciences/DMPK • Drove two programs from Hit Gen to LO-like profile (potency, selectivity, PK) in 12 months each • New Target proposal chosen for possible portfolio entry



The Janssen Pharmaceutical Companies of Johnson & Johnson

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• • Oct 2013 - Apr 2018

  • Co-inventor of DCs from three programs now each in Phase 1b blood cancers• Chemistry Project Leader for the gut-restricted JAK inhibitor program that delivered lorpucitinib• Led 13 internal/CRO chemists in discovering and selecting JNJ-64251330, later declared the DC• Successfully recommended either termination or HTS for multiple Pre-Portfolio programs• 20+ diligences, including Chemistry Lead for the JNJ/Rodeo Series A and JNJ/Aldeyra agreement

• • Mar 2011 - Oct 2013

  • Invented the "western portion" of a DC targeting the nuclear hormone receptor RORgt• Led the in vitro ADME effort in coordination with German partner Phenex• Directed CRO chemists in multiple chemotypes while prosecuting two targets



Johnson & Johnson

• United States
• Hospitals and Health Care
• 700 & Above Employee

• • Feb 2006 - Mar 2011

  • Chemistry Project Leader for Acetyl-CoA carboxylase (T2D/obesity)• Invented the lead series and led 3-12 chemists in discovering orally active pM binders• Made significant SAR contributions to a DC targeting the glucagon GPCR

• • Sep 2003 - Feb 2006

  • Chemistry Project Leader for the FLT3 kinase program (AML)• Led 3 chemists in discovering an oral FLT3 inhibitor with 85% tumor regression at 30 mpk • Invented the route for the orally active lead series; coordinated ADME and CADD• Scaled the Contract lead molecule for rat and dog tolerability studies



3-Dimensional Pharmaceuticals

• Cranbury, NJ

• Research Scientist

  • May 2001 - Sep 2003

  • Invented two series of thrombin protease inhibitors via structure based drug design (SBDD) • Contract molecule vetted for DC declaration; declined largely due to Ph3 rivaroxaban in-license • Provided route for fluorine introduction for Ph1/2a batch of thrombin inhibitor RWJ-671818 • Invented two series of thrombin protease inhibitors via structure based drug design (SBDD) • Contract molecule vetted for DC declaration; declined largely due to Ph3 rivaroxaban in-license • Provided route for fluorine introduction for Ph1/2a batch of thrombin inhibitor RWJ-671818



Scripps Research

• United States
• Research Services
• 700 & Above Employee

• Postdoctoral Fellow

  • May 1999 - Apr 2001

  • American Cancer Society Postdoctoral Fellow • Advisor: Prof. Chi-Huey Wong • Proposal funded: Fucosyltransferase inhibitors with potential utility in colon cancer • American Cancer Society Postdoctoral Fellow • Advisor: Prof. Chi-Huey Wong • Proposal funded: Fucosyltransferase inhibitors with potential utility in colon cancer